State Street Corp Ultragenyx Pharmaceutical Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, State Street Corp holds 2,664,077 shares of RARE stock, worth $119 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,664,077

Previous 2,697,101 1.22%

Holding current value

$119 Million

Previous $111 Million 33.5%

% of portfolio

0.01%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $1.33 Million - $1.96 Million	-33,024 Reduced 1.22%	2,664,077 $148 Million
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $5.77 Million - $7.96 Million	-154,149 Reduced 5.41%	2,697,101 $111 Million
Q1 2024 May 15, 2024	SELL	$43.02 - $53.69 $17.3 Million - $21.5 Million	-401,252 Reduced 12.34%	2,851,250 $133 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $21.7 Million - $33.7 Million	684,644 Added 26.66%	3,252,502 $156 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $3.58 Million - $4.78 Million	102,408 Added 4.15%	2,567,858 $91.5 Million
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $10.5 Million - $14.6 Million	-280,257 Reduced 10.21%	2,465,450 $114 Million
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $7.29 Million - $9.6 Million	-197,060 Reduced 6.7%	2,745,707 $110 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $12.9 Million - $17.8 Million	383,223 Added 14.97%	2,942,767 $136 Million
Q3 2022 Nov 15, 2022	BUY	$39.96 - $66.14 $4.09 Million - $6.76 Million	102,236 Added 4.16%	2,559,544 $106 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $23.3 Million - $43.4 Million	508,624 Added 26.1%	2,457,308 $147 Million
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $16.8 Million - $22.8 Million	269,843 Added 16.07%	1,948,684 $142 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $15.1 Million - $18 Million	204,976 Added 13.91%	1,678,841 $141 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $8.02 Million - $10.5 Million	102,990 Added 7.51%	1,473,865 $133 Million
Q2 2021 Aug 16, 2021	SELL	$92.19 - $115.71 $22.1 Million - $27.8 Million	-239,964 Reduced 14.9%	1,370,875 $131 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $7 Million - $11 Million	-65,460 Reduced 3.91%	1,610,839 $183 Million
Q4 2020 Feb 16, 2021	SELL	$84.4 - $177.39 $11.9 Million - $25 Million	-140,693 Reduced 7.74%	1,676,299 $232 Million
Q3 2020 Nov 10, 2020	SELL	$72.98 - $90.0 $11.8 Million - $14.5 Million	-161,252 Reduced 8.15%	1,816,992 $149 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $11.8 Million - $19.6 Million	-251,107 Reduced 11.26%	1,978,244 $155 Million
Q1 2020 May 11, 2020	BUY	$33.8 - $62.9 $75.4 Million - $140 Million	2,229,351 New	2,229,351 $99.1 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Ultragenyx Pharmaceutical Inc. Transaction History